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ABSTRACT 
Background and Objectives: The purpose of this study was to investigate the relationship between chronic atrial 
fibrillation (AF) and reduced pulmonary function. Subjects and Methods: Eighty-six chronic AF patients who 
were enrolled from annual health examination programs were studied using echocardiography and pulmonary 
function tests (PFT). Echocardiography and PFT matched for age, gender, and year performed were selected by the 
control group who had normal sinus rhythms. Patients with ejection fractions <50%, valvular heart disease, or 
ischemic heart disease were excluded. Results: In the chronic AF patients, the forced expiratory volume at one 
second (FEV1), FEV1%, and FEV1/forced vital capacity (FVC) were significantly reduced, and the right ventricular 
systolic pressure was significantly increased. Episodes of heart failure were more frequently associated with the 
chronic AF patients than the controls. In particular, the FEV1% had the most meaningful relationship to chronic 
AF after an adjustment for cardiovascular risk factors {p=0.003, Exp (B)=0.978, 95% confidence interval (CI): 
0.963-0.993}. Conclusion: Reduced FEV1%, which represents the severity of airway obstruction, was associated 
with chronic AF, and the greater the pulmonary function impairment, the greater the co-existence with AF and 
congestive heart failure in those with preserved left ventricular systolic function. (Korean Circ J 2009;39:372-377) 
 
KEY WORDS: Atrial fibrillation; Chronic obstructive lung disease; Pulmonary function tests; Forced expiratory 
volumes. 
 
 
Introduction 
 
Atrial fibrillation (AF) is frequently observed among 
supraventricular rhythm disorders. The prevalence of AF 
increases with age.
1-4) Pulmonary function, however, has 
a tendency to decrease progressively with age. The supra-
ventricular and ventricular arrhythmias are also common 
in chronic obstructive lung disease (COPD).
5-7) The rea-
sons are thought to be due to hypoxia, hypercarbia, pul-
monary hypertension, and myocardial ischemia, which 
are easily provoked by this limited ventilatory condi-
tion.
8-11) Furthermore, the frequencies of various types 
of arrhythmias are related to the temporal state of the 
pulmonary function in these patients. Cardiac arrhyth-
mias have a tendency to become aggravated when venti-
latory function deteriorates, and ameliorated when it 
improves; however, there is still controversy regarding the 
relationship between AF and reduced pulmonary function. 
The purpose of the current study was to determine 
the relationship between chronic AF and pulmonary 
function status among subjects with preserved left ven-
tricular systolic function (LVSF), and the difference in 
pulmonary function between the chronic AF group and 
the controls who presented with sinus rhythm (SR). 
 
Subjects and Methods 
 
Subjects 
Eighty-six chronic AF patients were enrolled from an 
annual health examination program between August 
2006 and June 2007, and were studied by echocardiogra-
phy and pulmonary function tests (PFT). Echocardio-
graphy and PFT matched for age, gender, and year per-
formed were selected by the control group who had 
normal sinus rhythm (SR) (Table 1). The subjects with a 
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left ventricular ejection fraction (LVEF) <50% and with 
valvular heart disease were excluded from the study. 
Also, any patients who had a history of percutaneous co-
ronary intervention, coronary artery bypass surgery, or 
Q-waves on a surface electrocardiogram (ECG) were ex-
cluded. Chronic AF was considered when AF was de-
tected consecutively >2 ECGs during a 1 month inter-
val. Finally, the subject was allocated into either the 
chronic AF group or the control group, depending on 
whether the cardiac rhythm was AF or normal SR. 
 
Assessment of risk factors 
The clinical data on risk factors for cardiovascular di-
sease that were related to AF were obtained from a com-
prehensive review of each patient’s medical record. Th-
erefore, each patient’s age, gender, and history of syste-
mic hypertension, diabetes mellitus, hyperlipidemia, and 
current smoking were investigated (Table 1). Systemic 
hypertension was defined by documenting the clinical 
diagnosis, or with evidence of an elevated systolic blood 
pressure of 140 mmHg and/or diastolic blood pressure 
of 90 mmHg, in the absence of any acute medical ill-
nesses. Diabetes mellitus was based on the clinical do-
cumentation of the condition, and whether the treat-
ment consisted of dietary therapy, oral hypoglycemic 
agents, and/or insulin. Hyperlipidemia was defined by 
a fasting total cholesterol level of 240 mg/dL and/or a 
low-density lipoprotein cholesterol level of 160 mg/dL, 
or by the use of cholesterol-lowering drugs. Current 
smoking referred to the active use of tobacco products at 
the time of enrollment in the study. Furthermore, des-
pite all the subjects presenting with preserved LVSF, a 
previous history of heart failure (HF) was also evaluat-
ed by the Framingham heart failure diagnostic criteria
12) 
because diastolic heart failure is not uncommonly as-
sociated with elderly patients and AF with a rapid ven-
tricular response is a well-known cause of reversible car-
diomyopathy. 
 
Echocardiographic examination 
In the echocardiographic study, the conventional two-
dimensional grayscale imaging, the pulsed or continuous 
wave Doppler study, and color Doppler imaging were 
performed according to previously validated recommen-
dations.
13) The semi-quantitative visual estimation and 
the modified Simpson’s method were used to assess 
LVSF, and the patients with a LVEF <50% by either of 
the two methods were excluded. The wall-motion score 
index was also applied to rule out cases with regional 
wall motion abnormalities, which were calculated by di-
viding the sum of the scores by the number of visualized 
segments. The left atrial (LA) dimension was measured 
at the point of end-systole just before the frame that 
preceded the mitral valve opening from the parasternal 
long-axis view. The peak systolic pressure of the right 
ventricle (pRVSPr) was carefully estimated using a previo-
usly validated method
13) when tricuspid regurgitation 
was present. Subjects with insufficient aortic or mitral 
valves (greater than a mild degree), stenosis of the valves, 
or structural abnormalities were excluded from the study. 
 
Evaluation of pulmonary function 
The forced expiratory volume at one second (FEV1), 
forced vital capacity (FVC), mean forced expiratory flow 
during the middle half of the FVC (FEF25-75%), and the 
ratio of the FEV1-to-FVC (FEV1/FVC) were measured 
Table 1. Baseline characteristics of the study population
Male (n=104)  Female (n=68)  Total (n=172) 
Parameter  AF 
(n=52) 
Control 
(n=52) 
p  AF  
(n=34) 
Control 
(n=34) 
p  AF  
(n=86) 
Control 
(n=86) 
p 
Clinical  parameters              
Age (years)  70.8±8.9 71.0±8.2  <0.900 70.5±9.1 71.2±8.6  <0.743*  70.7±8.9 71.1±8.3 0.757* 
BMI (kg/m
2) 22.3±3.1 22.7±3.2  <0.510 23.5±3.7 23.2±3.2  <0.782*  22.7±3.3 22.9±3.2 0.757* 
Height (m)  1.65±0.06  1.64±0.06  <0.468 1.51±0.06  1.50±0.07  <0.657*  1.59±0.09 1.59±0.09 0.560* 
Weight (kg)  60.7±9.3 61.1±9.5  <0.815 53.9±10.6  52.7±8.5  <0.608*  57.9±10.3 57.7±10.0 0.891* 
SBP (mmHg)  127±20 127±21  <0.984 128±20 125±19  <0.394*  128±19 126±20 0.586* 
DBP (mmHg)  78±17 78±12  <0.857 79±14 72±13  <0.033*  78±16 76±13 0.235* 
HR (bpm)  89.1±27.9  78.5±13.3  <0.018*  91.7±21.0  80.2±13.8  <0.010*  90.2±25.3 79.2±13.4 0.001* 
CVD risk factors (n)                   
Hyperlipidemia  06  07  <0.500*  05 4  <0.500*  11 11  0.590* 
Diabetes mellitus  09  04  <0.117*   12 3  <0.009*  21  07 0.003* 
Hypertension 14 03  <0.003*  18 8  <0.012*  32 11  <0.001* 
Current smoking  33  29  <0.275*  02 6  <0.129*  35 35  0.562* 
LVH  06  06  <1.000*  01 1  <1.000*  07  07 1.000* 
History of CHF  38  12  <0.001*  22 7  <0.001*  60 19  <0.001* 
*statistically significant. AF: atrial fibrillation, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, 
CVD: cardiovascular disease, LVH: left ventricular hypertrophy, CHF: congestive heart failure 
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by an electronic spirometer (Vmax 229 pulmonary func-
tion test/cardiopulmonary exercise testing instrument; 
Sensomedics, Yorba Linda, CA, USA). Also, the peak 
expiratory flow (PEF) and the expiratory flow at 25%, 
50%, and 75% FVC (FEF25%, FEF50%, and FEF75%, res-
pectively) were obtained from the flow-volume curve. 
Body plethysmography was applied to the measurement 
of the residual volume (RV), total lung capacity (TLC), 
airway resistance (Raw), and lung compliance (Gaw). 
The single breath technique with carbon monoxide was 
adopted for the measurement of the diffusion capacity 
of the lungs (DLCO). Specially-trained technicians per-
formed all of these measurements. Moreover, all of the 
values, except for the FEV1/FVC, which was measured 
with the spirometer, were automatically recalculated as 
percentile predicted values of the age- and gender-mat-
ched normal values using a computer software program. 
For example, the FEV1% was obtained from the follow-
ing formulae, in which H is the height (cm) and A is the 
age (year): FEV1%=0.092 H/2.54-0.032 A-1.26 (males); 
and FEV1%=0.089 H/2.54-0.025 A-1.932 (females). 
 
Statistical analysis 
The data are presented as the mean values ±standard 
deviations (SDs), unless otherwise stated. Continuous 
data on the two groups were compared with an indepen-
dent sample t-test, and categorical data were compared 
with a chi-square test. To reveal the relationship of the 
dichotomous data with the continuous data, logistic re-
gression analysis was applied (SPSS, version 13.0; SPSS 
Inc., Chicago, IL, USA). The statistical differences were 
considered significant at a p<0.05. 
 
Results 
 
Baseline characteristics 
The mean age, body mass index (BMI), and systolic 
and diastolic blood pressures (BP) of the AF group were 
similar to the controls. These findings, except for the di-
astolic BP in females, were also noted when comparing 
those parameters between the gender-specific subgroups. 
Regardless of gender, the resting heart rate (HR) of the 
AF group was significantly higher than the controls (p= 
0.001). The incidence of hyperlipidemia and current 
smoking did not differ between the AF and control gro-
ups. The AF group, however, had a significantly higher 
incidence of hypertension for both genders, and diabetes 
in females. The incidence of previous HF was much hi-
gher in the AF than in the control groups, as expected 
(60% vs. 19%, p<0.001). 
 
Characteristics of echocardiography and pulmo-
nary function tests of the atrial fibrillation and control 
groups 
The LA dimension and pRVSPr of the AF group were 
significantly greater than the controls (4.48±0.95 cm 
vs. 3.65±0.62 cm, p<0.001, and 43.7±12.9 mmHg vs. 
37.9±8.9 mmHg, p=0.006, respectively), even though 
the LVEF of the two groups was similar (Table 2). 
Among the parameters of the PFT, the FEV1, FEV1%, 
and FEV1/FVC were significantly lower in the AF group 
than the control group. The other parameters were not 
statistically different between the two groups (Table 2). 
Therefore, ventilatory dysfunction, rather than SR, ap-
peared to be more associated with the AF group. When 
logistic regression was performed with the FEV1, FEV1%, 
and FEV1/FVC as a function of the cardiac rhythm and 
with the adjustment of risk factors {hypertension, dia-
betes mellitus, and congestive heart failure (CHF)}, FEV 
1% had the most meaningful relationship with AF {p 
=0.003, Exp (B)=0.978, 95% confidence interval (CI): 
0.963-0.993}; FEV1 also exhibited a meaningful relation-
ship {p=0.019, Exp (B)=0.520, 95% CI: 0.301-0.897}. 
An inverse correlation between FEV1% and the pRVSPr 
was observed in this study, which was in agreement with 
the secondary pulmonary hypertension results of the 
reduced ventilatory function. Furthermore, an increase 
in the pRVSPr represented a close relationship with 
Table 2. Characteristics of echocardiographic examination and 
pulmonary function tests 
Parameters  AF group 
(n=86) 
Control 
(n=86) 
p 
Echocardiographic    
LA dimension (cm)  4.48±0.95 3.65±0.62  <0.001* 
pRVSPr (mmHg)  43.7±12.9 37.9±8.90  <0.006* 
LVEF (%)  58.3±8.4 58.5±7.40  <0.933* 
PFT      
FEV1 1.49±0.52 1.70±0.60  <0.017* 
FEV1% 69.5±20.4 79.9±22.7  <0.003* 
FVC 2.19±0.75 2.39±0.87  <0.208* 
FEV1/FVC 29.2±11.4 34.6±12.7  <0.039* 
PEF 3.52±1.30 4.05±1.65  <0.065* 
FEF25-75% 1.12±0.75 1.24±0.67  <0.391* 
FEF25% 2.12±1.56 2.65±1.75  <0.068* 
FEF50% 1.34±0.86 1.70±0.91  <0.016* 
FEF75% 0.49±0.35 0.50±0.29  <0.849* 
RV 2.84±1.28 2.45±1.18  <0.146* 
TLC 5.01±1.23 4.95±1.64  <0.850* 
Raw 3.32±1.47 3.14±1.79  <0.615* 
Gaw 0.38±0.20 0.42±0.22  <0.351* 
DLCO 12.9±4.7 13.6±5.1  <0.554* 
AF: atrial fibrillation, LA: left atrium, pRVSPr: peak right ventri-
cular systolic pressure, LVEF: left ventricular ejection fraction, PFT:
pulmonary function test, FEV1: forced expiratory volume at on se-
cond, FVC: forced vital capacity, FEV1/FVC: ratio of the FEV1 to 
FVC, PEF: peak expiratory flow, FEF25-75%: mean forced expiratory 
flow during the middle half of the FVC, FEF25%: expiratory flow at 
the 25%, FEF50%: expiratory flow at the 50%, FEF75%: expiratory 
flow at the 75%, RV: residual volume, TLC: total lung capacity, 
Raw: airway resistance, Gaw: lung compliance, DLCO: diffusion 
capacity of the lung    
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AF {p=0.009, Exp (B)=1.052, 95% CI: 1.013-1.092}. 
 
Categorization of the subjects according to the 
forced expiratory volume at one second range 
The FEV1% values were categorized into three sub-
groups by applying cutoff levels of 80% and 60% of 
the predictive value in both groups, which were the 
levels adopted in many previous studies. In the cases in 
which the FEV1% was >80% of the predictive value, 
SR was most frequently observed. AF was most com-
monly observed in cases in which the FEV1% was <60% 
(Fig. 1). Using the Mantel-Haenszel estimation, the prev-
alence of AF in the cases with a FEV1% between 60% 
and 80%, and <60% exhibited odds ratios (ORs) of 
2.265 (p=0.019) and 2.887 (p=0.007), respectively, when 
compared to cases with a FEV1% >80%. The prevalence 
of AF in the cases with a FEV1% <60% did not differ 
from the prevalence of AF in the cases with a FEV1% 
between 60% and 80% (OR=1.221, p=0.619). 
 
Relationship between congestive heart failure and 
atrial fibrillation and forced expiratory volume at one 
second in patients with preserved LVSF 
A normal ejection fraction can exist in patients with 
symptoms of heart failure, and is regarded as an indica-
tion of diastolic heart failure. Moreover, AF can induce 
an enhanced ventricular response, which will result in 
the aggravation of heart failure. In this study, a history 
of CHF was observed more frequently in the AF group 
than in the control group. The FEV1% had a meaningful 
relationship with CHF {p=0.008, Exp (B)=0.980, 95% 
CI: 0.965-0.995}. The mean value of the FEV1% also 
differed significantly according to whether or not the 
patient had a history of heart failure (69.6±19.7% vs. 
79.0±23.2%, p=0.006). The prevalence in the patients 
with a FEV1% between 60% and 80% and <60%, had 
an OR of 3. 1 02 (p=0.003) and 2.910 (p=0.007), res-
pectively, compared to a FEV1% >80% (Fig. 2). The pre-
valence of CHF in the patients with a FEV1% <60% did 
not differ from the prevalence of CHF in the patients 
with a FEV1% between 60% and 80% (OR=0.938, 
p=0.871). 
 
Discussion 
 
In several studies that used multivariate analyses with 
correction for age, the major risk factors for AF were hy-
pertension, heart failure, diabetes mellitus, and valvular 
heart disease. Bundle branch block and left ventricular 
hypertrophy were regarded as potential predictors of AF.
14) 
However, the results regarding the relationship between 
AF and pulmonary function have been discordant. The 
FEV1% was reported to be an important predictive fac-
tor for AF in the Copenhagen City Heart Study,
15) which 
was comprised of a healthy age-stratified cohort (n= 
13,430) with a prospective design. Psaty et al.
16) also re-
ported that the occurrence of AF was related to reduced 
pulmonary function in the Cardiovascular Health Study 
(n=5,201). In contrast, the Renfrew/Paisley study
14) (n= 
15,406) did not demonstrate a significant correlation 
between the FEV1% and AF, whereas it reported the 
traditional major risk factors to be significant. Similarly, 
the Framingham study
1) (n=4,731) found no relationship 
between the FEV1 and AF. 
To address these discordant results on the relationship 
between AF and reduced pulmonary function, the cur-
rent study was conducted as a case-control study with 
consecutive enrollment of patients. In this study, a re-
duced FEV1% was significantly associated with chronic 
AF, and this finding was supported by the results of the 
preceding two studies. The Renfrew/Paisley study,
14) 
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Fig. 1. Histogram showing percentage of atrial fibrillation and
normal sinus rhythm groups, stratified into FEV1% categories.
FEV1%: forced expiratory volume at one second, AF: atrial 
fibrillation, NSR: normal sinus rhythm, NS: not significant. 
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Fig. 2. Histogram showing relationship of heart failure with atrial
fibrillation, stratified into FEV1% categories. FEV1%: forced 
expiratory volume at one second, AF: atrial fibrillation, NSR: nor-
mal sinus rhythm, NS: not significant, HF: heart failure.  
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which reported the opposite results, observed a small 
number of new-onset AF cases (n=19) after a short fol-
low-up and reported cardiomegaly as the most powerful 
predictor for AF (OR=14.0) after a long-term follow-up, 
which means that subjects with a decreased LVSF were 
enrolled. In the Framingham study,
1) there was a high 
rate of heart disease. For example, the prevalence of val-
vular heart disease was 7% in males and 9% in females; 
patients with valvular heart disease were excluded from 
our study. Therefore, the inclusion of these strong risk 
factors may have obscured the relationship between the 
FEV1% and AF in the two aforementioned studies. 
The pathophysiologic mechanisms that connect re-
duced pulmonary function to chronic AF have not been 
clearly determined, but there are several suggestive ex-
planations. With respect to the first explanation, recent 
observations have indicated that ectopic beats that initi-
ate AF often originate in the pulmonary veins.
17)18) Re-
duced ventilatory function could easily trigger ectopic 
beats by deterioration of the blood gas composition, 
such as occurs with hypoxia, and pulmonary hypertension 
results in stress on the right atrium and connecting ves-
sels, thus perpetuating AF. In this study, the pulmonary 
artery pressure (pPAPr) in the AF group was significant-
ly higher than the control group. The second explanation 
can be assumed to be the chronic inflammatory proces-
ses that involve the cardiopulmonary system. Anatomi-
cally, the pulmonary circulation directly drains into the 
left atrium. Also, obstructive airway disease is the result 
of chronic inflammation of the airways of the lungs that 
consequently manifests in reduced FEV1 or FEV1%. 
Recent studies have reported that these processes are as-
sociated with an increase in several inflammation-sensi-
tive proteins (ISP), such as high sensitivity-C-reactive pro-
tein (CRP), fibrinogen, and cytokines, including inter-
leukin-6 (IL-6), IL-1, tumor necrosis factor (TNF)-α, 
and the complement system.
19-22) For example, the level 
of hs-CRP is known to increase in patients with AF; 
hsCRP is synthesized from the liver by stimulation of 
IL-6, -11, and -12 and is frequently associated with fi-
brosis of the atrial tissue and myocarditis on histologic 
examination. Fibrosis of the atrial tissue is now accept-
ed as a perpetuating factor of AF. Therefore, it can be 
speculated that chronic inflammation is a plausible me-
chanism that connects reduced pulmonary function 
with chronic AF, which was clinically manifested as the 
relationship between chronic AF and decreased FEV 
1% in this study. The third explanation involves the 
hemodynamic consequences of AF. It is well-recognized 
that the loss of the atrial contraction decreases cardiac 
output and causes an increase in backward pressure and 
congestion of the lungs, especially the small airways. 
As a consequence, those hemodynamic alterations not 
only result in atrial dilation, wall stretching, and elec-
trical remodeling of the atrial tissue, but also hinders 
the ventilatory function of the lungs.
23)24) In this study, 
when comparing the parameters for estimating small air-
way function, FEF25-75%, FEF25%, and FEF75%, but not 
FEF50%, did not differ between the groups. Also, the 
DLCO exhibited no manifestations compatible with 
that assumption. Therefore, the results of this study do 
not sufficiently support the aforementioned assumpt-
ion. However, the possibility that these parameters may 
present meaningful results by an exaggeration of the 
hemodynamic effects, such as an exercise challenge, can-
not be abandoned entirely because these parameters were 
measured only during the resting state. 
In addition, a close relationship existed between the 
FEV1% and symptomatic episodes of heart failure in the 
AF group {p=0.011, Exp (B)=0.965, 95% CI: 0.939-
0.002} after adjustment for the risk factors (hypertension 
and diabetes mellitus), whereas no relationship was ob-
served in the control group. AF can cause heart failure 
through a rapid ventricular response, which results in 
an elevated end diastolic pressure and backward conges-
tion, even in patients with a normal ejection fraction. 
Hence, these findings imply that reduced ventilatory 
function as also attributed to heart failure from a rapid 
ventricular rate during AF. 
 
Clinical implications and limitations 
In clinical practice, β -blockers, which can adversely af-
fect ventilation, are commonly administered to alleviate 
the ventricular rate in AF with preserved LVSF, as are 
β-agonists, which can aggravate the cardiac rhythm to 
manage reduced lung function. Prudent use of those dru-
gs is likely to be needed because chronic AF co-existing 
with reduced ventilatory function was not rare in this 
study. 
Similar to other case control studies, the cause-and-
effect relationship and the underlying mechanisms were 
not clearly determined in this study, but the FEV1% was 
revealed to be a co-morbid factor for chronic AF. Thus, 
a further study on these issues should be pursued. 
In conclusion, this study showed that reduced pul-
monary function was related to AF as a co-morbid factor, 
and was clearly attributed to hemodynamic alterations, 
such as congestion during chronic AF, even when a nor-
mal ejection fraction was present. 
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